Estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) breast cancer (BC) not only have markedly different clinical prognoses and treatment decisions [1–3], but also are molecularly and etiologically distinct. This evidence concerns the gene ESR1 and breast cancer.